MAPK3 and ocular melanoma: As reported in Figure 6D, dasatinib clearly inhibits Erk1/2 activity at 7 and 9 days of treatment and strongly reduces, at 11 days, its activation by OM, thus suggesting that this dasatinib effect on MAPK inhibition might have a role in the commitment of MSCs towards adipogenesis.